There is a new CRC Phase 1 trial just added to clinicaltrials .gov
NCT02659631 for an experimental drug called "PF-06671008" which targets CRC tumors with the P-cadherin cell marker.
https://clinicaltrials.gov/ct2/show/NCT ... 631&rank=1
There are specifically recruiting for CRC, including MSS. You would have to call for locations, not listed yet.
It is a Phase 1 trial so they will be starting with low dose & looking for safety in addition to efficacy.
Pfizer hasn't publicly released what exactly the drug is (as far as I can tell) but looking at its immune related exclusion criteria & their recent publication history, I think there is good chance it is a P-cadherin x CD3 bifunctional DART which is a form of immunotherapy - but that is just an educated guess at this point.
They presented a P-cadherin x CD3 bifunctional DART at a cancer conference last Spring http://cancerres.aacrjournals.org/conte ... ement/2476
If it is a DART, that strategy basically physically pulls a T-Cell right up against a tumor cell expressing the target (in this case “P-cadherin”) - once it is pulled next to it, tumor cell killing should hopefully commence. If you are familiar with the clinical trial drug “MGD007” this is the same concept just using a different cancer cell marker. Not as subtle a solution as some other immunotherapy options but... with an immunologically cold tumor like MSS-CRC, some brute force may be needed.
I'll update if it becomes confirmed what exactly PF-06671008 is -- as I said, just an educated guess at this point but it is probably their DART.